Fig. 1: TKI-resistant HCC is negatively associated with immune-related signatures and show altered infiltration of immune cells. | Cell Death & Disease

Fig. 1: TKI-resistant HCC is negatively associated with immune-related signatures and show altered infiltration of immune cells.

From: Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer

Fig. 1

A Gene Set Enrichment Analysis (GSEA) of TKI sensitive (Sen) versus TKI-resistant (TKIRes) samples; left - Gene Oncology Biological Process (GOBP) and right - Hallmark. B Schematic of sorafenib (Sora), lenvatinib (Lenva) and vehicle control (DMSO) treatment in C57BL/6 N mice bearing xenografts established from murine HCC cell line RIL-175. C Tumor growth curves of C57BL/6 N mice bearing RIL-175 xenografts treated with Sora, Lenva, or DMSO. D Bar charts showing the percentages of intratumoral immune cell populations and CD8+/Foxp3+ ratio in mice treated with Sora, Lenva or DMSO (n = 7 per group). Data representative of two independent experiments. E Representative H&E and IHC images showing CD8α+ and CD103+ cells in the tumor sections treated with either Sora, Lenva, or DMSO. Scale bar = 100 µm and 25 µm (inset). Red arrows indicate positive signals of CD8α and CD103. F Bar charts showing the quantification of CD8α+ and CD103+ cells in three independent, randomly selected fields. *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant on one-way ANOVA with Bonferroni’s multiple comparisons test.

Back to article page